Pharmacological Effects and Candidate Bioactive Constituents of Huanglian Wendan Decoction in Experimental Metabolic Syndrome: Multi-Omics Analysis of Gut-Liver Metabolism and NLRP3 Signaling
- 1Heilongjiang University of Chinese Medicine
Abstract
Background: Chronic low-grade inflammation and gut microbiota dysbiosis contribute to metabolic syndrome (MS). Huanglian Wendan Decoction (HLWDD) is a defined multi-herbal formulation used in Chinese medicine, but its effects on gut microbiota-associated metabolism and NLRP3 inflammasome signaling remain unclear. Objective: This study evaluated the pharmacological effects and candidate absorbed bioactive constituents of HLWDD in experimental MS. Methods: A high-fat, high-sugar diet-induced rat model of MS was assessed using metabolic, biochemical, histological, molecular, and multi-omics endpoints. Gut metagenomics, untargeted metabolomics of liver and colonic contents, liver transcriptomics, and UPLC-HRMS/MS analysis of serum-absorbed constituents were integrated with network pharmacology and molecular docking. Baicalin was further evaluated in PA-BSA-treated HepG2 cells. Results: HLWDD ameliorated obesity, dyslipidemia, hepatic steatosis, and systemic inflammation and attenuated NLRP3 inflammasome-related signaling. Multi-omics analysis identified nine shared differential metabolites and a strong positive association between Faecalibacterium and butyrate. Thirty-two serum-absorbed constituents were tentatively identified. Baicalin showed favorable predicted interactions with NLRP3 (-5.82 kcal/mol) and CASP1 (-5.41 kcal/mol) and concentration-dependently suppressed NLRP3 inflammasome-related signaling in HepG2 cells; the highest concentration increased intracellular butyrate. Conclusion: HLWDD ameliorated metabolic and inflammatory abnormalities in experimental MS in association with restoration of gut-liver metabolic homeostasis and attenuation of NLRP3 inflammasome signaling. Baicalin emerged as a candidate absorbed bioactive constituent.
Related
- GNPS-assisted identification of bioactive constituents from Scoparia dulcis and their anti-inflammatory mechanisms via network pharmacology and experimental validation.
- Bee-Derived Products in Neurodegenerative Diseases: Bioactive Constituents, Redox-Modulating Mechanisms, Evidence, and Translational Perspectives
- Cinnamon (Cinnamomum spp.): Phytochemical Constituents and Biological Potential from a Pharmacological Perspective.
- A Comprehensive Review on Ferula oopoda (Boiss. and Buhse) Boiss.: Bioactive Compounds and Pharmacological Significance.
- Direct pharmacological AMPK activation inhibits mucosal SARS-CoV-2 infection by reducing lipid metabolism, restoring autophagy flux and the type I IFN response
BibTeX
@misc{wang2026pharmacological,
title = {{Pharmacological Effects and Candidate Bioactive Constituents of Huanglian Wendan Decoction in Experimental Metabolic Syndrome: Multi-Omics Analysis of Gut-Liver Metabolism and NLRP3 Signaling}},
author = {H. WANG and K. WANG and J. Shi and J. P. Zhu},
howpublished = {bioRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.05.756920},
url = {https://www.biorxiv.org/content/10.64898/2026.10.05.756920v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - Pharmacological Effects and Candidate Bioactive Constituents of Huanglian Wendan Decoction in Experimental Metabolic Syndrome: Multi-Omics Analysis of Gut-Liver Metabolism and NLRP3 Signaling
AU - H. WANG
AU - K. WANG
AU - J. Shi
AU - J. P. Zhu
PY - 2026
DA - 2026/10/05
PB - bioRxiv
DO - 10.64898/2026.10.05.756920
UR - https://www.biorxiv.org/content/10.64898/2026.10.05.756920v1
AB - Background: Chronic low-grade inflammation and gut microbiota dysbiosis contribute to metabolic syndrome (MS). Huanglian Wendan Decoction (HLWDD) is a defined multi-herbal formulation used in Chinese medicine, but its effects on gut microbiota-associated metabolism and NLRP3 inflammasome signaling remain unclear. Objective: This study evaluated the pharmacological effects and candidate absorbed bioactive constituents of HLWDD in experimental MS. Methods: A high-fat, high-sugar diet-induced rat model of MS was assessed using metabolic, biochemical, histological, molecular, and multi-omics endpoints. Gut metagenomics, untargeted metabolomics of liver and colonic contents, liver transcriptomics, and UPLC-HRMS/MS analysis of serum-absorbed constituents were integrated with network pharmacology and molecular docking. Baicalin was further evaluated in PA-BSA-treated HepG2 cells. Results: HLWDD ameliorated obesity, dyslipidemia, hepatic steatosis, and systemic inflammation and attenuated NLRP3 inflammasome-related signaling. Multi-omics analysis identified nine shared differential metabolites and a strong positive association between Faecalibacterium and butyrate. Thirty-two serum-absorbed constituents were tentatively identified. Baicalin showed favorable predicted interactions with NLRP3 (-5.82 kcal/mol) and CASP1 (-5.41 kcal/mol) and concentration-dependently suppressed NLRP3 inflammasome-related signaling in HepG2 cells; the highest concentration increased intracellular butyrate. Conclusion: HLWDD ameliorated metabolic and inflammatory abnormalities in experimental MS in association with restoration of gut-liver metabolic homeostasis and attenuation of NLRP3 inflammasome signaling. Baicalin emerged as a candidate absorbed bioactive constituent.
ER -